Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05384041
Other study ID # FW-200-05
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 28, 2022
Est. completion date October 24, 2022

Study information

Verified date February 2024
Source Fisher Wallace Laboratories
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in adults.


Description:

This prospective, fully remote, randomized, controlled, triple-blind (subject, Principal Investigator, Sponsor) pivotal study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in adults.


Recruitment information / eligibility

Status Completed
Enrollment 255
Est. completion date October 24, 2022
Est. primary completion date September 30, 2022
Accepts healthy volunteers No
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: 1. Age 21-65 years and a resident of the United States of America 2. Meets DSM-5 diagnostic criteria for moderate to severe Major Depressive Disorder 3. Baseline BDI-II score between 20 and 63, inclusive (in moderate to severe range) 4. Able to receive packages to their home via United Parcel Service/Fedex/United States Postal Service or other delivery service 5. Willing and able to send and receive study related text messages on an internet capable mobile device throughout the duration of the study 6. Owns and uses a personal, verifiable email address 7. Able to commit to two (2) 20-minute treatment sessions per day for 4 weeks, one treatment upon waking for the day and one treatment before going to bed 8. Willing to abstain from use of recreational drugs, hypnotics, steroids, and/or marijuana products through study completion 9. Willingness to not initiate treatment for a mental health issue during the course of the study 10. Fluent in English 11. Sexually active females of childbearing potential willing to commit to practicing at least one or more of the following methods of contraception during the study: intrauterine device (IUD), barrier method in combination with a spermicide, oral/hormonal contraception, or abstinence 12. In the opinion of the investigator, able to comply with study requirements and complete the study Exclusion Criteria: 1. History of suicide attempt or active suicidal ideation with plan or intent in the past 30 days. 2. In the opinion of the investigator, considered high risk of suicide 3. Previous hospitalization or institutionalization for mental health condition within one year of study entry 4. Underwent electronic brain stimulation or neuromodulation within the past one year, including CES, transcranial magnetic stimulation, electroconvulsive therapy, and deep brain stimulation 5. Modification of prescription medications that affect the nervous system (e.g., psychotropic medications) within 30 days of study entry 6. Use of recreational drugs, hypnotics, steroids, and/or marijuana products in the past 30 days 7. History of alcohol use disorder or other substance use disorder in the past 12 months 8. Females currently pregnant or planning to conceive during study participation, or unwilling to comply with birth control requirements 9. Known history of heart disease 10. Known history of trigeminal neuralgia 11. Implanted with an electronic device such as a defibrillator, deep brain stimulator, or pacemaker 12. Unstable medical condition including any condition requiring hospitalization or change in treatment in the prior 30 days 13. Legally blind and/or deaf and without in-home care service to assist with study participation 14. Meets M.I.N.I. assessment criteria for, or has been diagnosed with, any of the following: Bipolar I disorder, bipolar II disorder, other specified bipolar and related disorder, panic disorder, agoraphobia, social anxiety disorder (social phobia), obsessive-compulsive disorder, posttraumatic stress disorder, alcohol use disorder in the past 12 months, substance use disorder (non-alcohol) in the past 12 months, any psychotic disorder (e.g., schizophrenia, schizoaffective disorder), major depressive disorder with psychotic features, anorexia nervosa, bulimia nervosa, binge-eating disorder, generalized anxiety disorder, any cognitive or developmental disorder (e.g., autism, Down's Syndrome), any personality disorder or psychiatric disorder that may interfere with study participation 15. Current participation in another investigational study or participated in an investigational study within the past 30 days 16. In the opinion of the investigator, may not be able to comply with study requirements 17. Any employee, family member, or personal associate of the Sponsor or their designees conducting the study

Study Design


Intervention

Device:
Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)
The indicated use in adults (ages 21-65 years) is for 20 minutes twice daily, upon waking for the day and at bedtime. The treatment period of the intervention will have a duration of four weeks.
Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)
The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.

Locations

Country Name City State
United States New York Neuromodulation Medical, PLLC New York New York

Sponsors (3)

Lead Sponsor Collaborator
Fisher Wallace Laboratories Climb Technologies, Inc., NAMSA

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the Beck Depression Inventory Second Edition (BDI-II) at Week Two Compared to Baseline. The Beck Depression Inventory Second Edition (BDI-II) is a multiple-choice self-report inventory that assesses severity of depression. The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). The minimum score is 0 and the maximum score is 63, with a higher score indicating more severe depressive symptoms.
The candidate subject's BDI-II score must be within the range of 20 to 63 indicating moderate to severe Major Depressive Disorder.
Change at week two compared to baseline.
Secondary Change in the Beck Depression Inventory Second Edition (BDI-II) at Weeks One and Four Compared to Baseline. The Beck Depression Inventory Second Edition (BDI-II) is a multiple-choice self-report inventory that assesses severity of depression. The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). The minimum score is 0 and the maximum score is 63, with a higher score indicating more severe depressive symptoms.
The candidate subject's BDI-II score must be within the range of 20 to 63 indicating moderate to severe Major Depressive Disorder.
Change at weeks one and four compared to baseline.
Secondary Change in the Patient Health Questionnaire-9 (PHQ-9) at Weeks One, Two, and Four Compared to Baseline. The Patient Health Questionnaire-9 (PHQ-9) is a 9-item scale covering the Diagnostic and Statistical Manual, 5th Edition (DSM-5) for Major Depressive Disorder, with a diagnostic algorithm and score-based assessment of presence and severity of depression. The minimum score is 0 and the maximum score is 27, with a higher score indicating more severe depressive symptoms. Change at weeks one, two, and four compared to baseline.
Secondary Change in the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) at Weeks One, Two, and Four Compared to Baseline. The Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) is a 16-item rating scale that assesses nine criterion symptom domains to diagnose a major depressive episode. The minimum score is 0 and the maximum score is 27, with a higher score indicating more severe depressive symptoms. Change at weeks one, two, and four compared to baseline.
Secondary Beck Depression Inventory Second Edition (BDI-II) Responder Rate by Time Point (% of Subjects With a 50% or Better Improvement in Score From Baseline). The Beck Depression Inventory Second Edition (BDI-II) is a multiple-choice self-report inventory that assesses severity of depression. The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). The minimum score is 0 and the maximum score is 63, with a higher score indicating more severe depressive symptoms.
The candidate subject's BDI-II score must be within the range of 20 to 63 indicating moderate to severe Major Depressive Disorder.
Four weeks following baseline.
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A